Audentes Therapeutics
Audentes is a biotechnology company that employs gene therapy technology to develop treatments for people with rare muscle diseases.
Business Model:
Revenue: $0
Employees: 201-500
Industries / Tags:
Detailed Audentes Therapeutics Information
Audentes Therapeutics was acquired by
Astellas Pharma.
The acquisition happend on 2019-12-02.
Details of the transaction were not public
Acquirer
Geographic Data
Address:
City: San Francisco
State: California
Zip:
Country: United States
Financial Info
Stage:
post ipo equity
Raised Last:
$163M
Raised Total:$531M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Audentes Therapeutics doing business as Astellas Gene Therapies, Inc. is a biotechnology company that serves as the Gene Therapy Center of Excellence. The company is divided into three divisions that specialize in gene therapy research, including technical operations, medical and development, and future commercialization of gene therapy programs. Audentes Therapeutics was acquired by Astellas Pharma on January 15, 2020.
Contact Phone:
Contact Email:
Audentes Therapeutics went public on 7/19/2016 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
7/19/2016
Ticker Symbol:
BOLD
IPO Price:
$15/share
Amount Raised:
$75M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 10/2018 | Post-IPO Equity | $162.5M | 12/2014 | Series B | 6 | $42.5M |
Deerfield Versant Ventures Venrock Sofinnova Investments OrbiMed 5AM Ventures Deerfield |
10/2015 | Series C | 13 | $65M |
Venrock 5AM Ventures Sofinnova Investments Deerfield Redmile Group Asset Management Ventures (AMV) RA Capital Management OrbiMed Foresite Capital Rock Springs Capital Redmile Group Sofinnova Investments Versant Ventures T. Rowe Price Venrock 5AM Ventures Sofinnova Investments Deerfield Redmile Group Asset Management Ventures (AMV) RA Capital Management OrbiMed Foresite Capital Rock Springs Capital Redmile Group Sofinnova Investments |
7/2013 | Series A | 3 | $30M |
OrbiMed Versant Ventures 5AM Ventures OrbiMed |
1/2018 | Post-IPO Equity | $231.4M |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 9/2015 | CardioGen Sciences |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
